Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

Boundless Bio’s freshman year on the public markets hasn’t been easy, with “modest” layoffs in the summer followed by news ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

The data include an interim look at the dose-escalation portion of a phase 2 trial assessing the adenosine A2A receptor ...

LAB eN 2, the drug discovery accelerator launched by Evotec and Novo Nordisk in September 2023, has unveiled its first three ...

PeptiDream, the Japanese biopharma with a penchant for deal-making, has a new bargaining chip in its hand in the red-hot ...